PRESS RELEASE published on 07/01/2024 at 06:50, 2 years 4 months ago Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2) Formycon receives FDA approval for FYB203/AHZANTIVE(R) (aflibercept-mrbb), a biosimilar to Eylea(R). The approval highlights Formycon's expertise and commitment to providing effective and affordable biosimilar therapies for retinal diseases. FDA Approval Biosimilar Formycon Eylea Retinal Diseases
BRIEF published on 06/28/2024 at 23:55, 2 years 4 months ago FDA Approves Biosimilar FYB203/AHZANTIVE® for Retinal Diseases FDA Approval Biosimilar Eylea Retinal Diseases Treatment Approval
BRIEF published on 06/28/2024 at 23:55, 2 years 4 months ago La FDA approuve le biosimilaire FYB203/AHZANTIVE® pour les maladies rétiniennes Approbation De La FDA Biosimilaire Eylea Maladies De La Rétine Approbation Du Traitement
PRESS RELEASE published on 06/28/2024 at 23:50, 2 years 4 months ago EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb) FDA grants approval for Eylea biosimilar FYB203/AHZANTIVE by Formycon AG and Klinge Biopharma GmbH. Biosimilar approved for nAMD and other retinal diseases FDA Approval Retinal Diseases Eylea Biosimilar FYB203/AHZANTIVE Neovascular Age-Related Macular Degeneration
BRIEF published on 06/13/2024 at 15:35, 2 years 5 months ago Formycon Announces AGM Results and Board Changes Shareholders 2023 Financial Year Supervisory Board AGM Formycon
BRIEF published on 06/13/2024 at 15:35, 2 years 5 months ago Formycon annonce les résultats de l'AGA et les changements au conseil d'administration Actionnaires Exercice 2023 Conseil De Surveillance AGA Formycon
PRESS RELEASE published on 06/13/2024 at 15:30, 2 years 5 months ago Formycon reports on the results of the Annual General Meeting Formycon AG reports on the results of its Annual General Meeting, including approvals of agenda items, new Supervisory Board members, and election of new Chairman Annual General Meeting Shareholders Supervisory Board Formycon AG Biosimilars
BRIEF published on 06/13/2024 at 10:46, 2 years 5 months ago First Berlin Equity Research Lowers Price Target for Formycon AG to €80 First Berlin Equity Research Buy Recommendation Formycon AG FYB202 Stelara
BRIEF published on 06/13/2024 at 10:46, 2 years 5 months ago First Berlin Equity Research abaisse son objectif de cours pour Formycon AG à 80 € Formycon AG Recommandation D'achat FYB202 Première Recherche Sur Les Actions À Berlin Stelara
PRESS RELEASE published on 06/13/2024 at 10:41, 2 years 5 months ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research GmbH reaffirms Buy recommendation for Formycon AG and lowers price target to €80 amid expected launch of lucrative biosimilar FYB202. Analyst Simon Scholes provides insights on Formycon's future prospects and market dynamics Stock Market Analysis Buy Recommendation Formycon AG First Berlin Equity Research GmbH Biosimilar
Published on 11/20/2026 at 02:00, 9 hours 5 minutes ago PPX Mining Announces Completion of Debt Settlement
Published on 11/19/2026 at 23:30, 11 hours 35 minutes ago EQ Inc. Reports Third Quarter 2026 Financial Results
Published on 11/19/2026 at 23:00, 12 hours 5 minutes ago Redwood AI Reports Positive Interim Q-SAFE Findings Supporting Quantum-Assisted Chemical Safety Screening
Published on 11/19/2026 at 22:35, 12 hours 30 minutes ago Pampa Medina Drilling Intersects 102m of 1.0% Cu and 5.1g/t Ag from SPRD-21; 22m of 2.1% Cu and 10g/t Ag from SPRD-18; and 8m of 3.21% Cu and 27.5g/t Ag from SPRD-24
Published on 11/19/2026 at 22:25, 12 hours 40 minutes ago Kidoz Reports Record Nine-Month Revenue of US$9,900,750
Published on 11/20/2026 at 10:59, 5 minutes ago EQS-Adhoc: Revenue decreases by approximately 28.6% in the first half of the financial year // Positive revenue and earnings outlook for the 2026/2027 financial year remains unchanged
Published on 11/20/2026 at 10:34, 30 minutes ago Finexity AG: mwb analytics initiates coverage of Finexity AG with Buy rating and EUR 14.00 price target
Published on 11/20/2026 at 10:13, 51 minutes ago JIMMY encourages a closer look at water purifiers beyond the price tag
Published on 11/20/2026 at 10:04, 1 hour ago Original-Research: Energiekontor AG (von First Berlin Equity Research GmbH): Buy
Published on 11/20/2026 at 10:00, 1 hour 4 minutes ago Helvetia’s total loss insurance wins Swiss Insurance Innovation Award
Published on 11/19/2026 at 19:00, 16 hours 5 minutes ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR
Published on 11/19/2026 at 19:00, 16 hours 5 minutes ago MR.BRICOLAGE : PERSPECTIVES POUR L'EXERCICE 2026
Published on 11/19/2026 at 08:30, 1 day 2 hours ago Data sovereignty: Cegedim opens EB6, a next-generation datacenter for AI and high-density computing
Published on 11/19/2026 at 08:30, 1 day 2 hours ago Souveraineté des données : Cegedim ouvre EB6, un datacenter nouvelle génération pour l'IA et la haute densité